L'intérêt à découvert pour Mesoblast donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Mesoblast. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Mesoblast (NASDAQ:MESO) Stock, Rapport sur les intérêts à découvert

Mesoblast

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Mesoblast Limited - American Depositary Shares

Mesoblast Ltd

Meso Numismatics Inc

Commercial Metals Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMC#NYSE">CMC</a>) will release its third-quarter earnings results before the <a href="https://www.benzinga.com/quote/CMC/earnings">opening bell on Monday, June 23.</a>
Analysts expect the company to report quarterly earnings at 84 cents per share, down from $1.02 per share in the year-ago period. Commercial Metals is projected to report quarterly revenue of $2.04 billion, compared to $2.08 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On March 20, Commercial Metals reported second-quarter 2025 results, with net sales down 5.1% year-over-year to $1.754 billion, broadly in line with the analyst expectations of $1.746 billion.
With the recent buzz around Commercial Metals, some investors may be eyeing potential gains from the company's dividends too. As of now, Commercial Metals offers an annual dividend yield of 1.47%, which is a quarterly dividend amount of 18 cents per share (72 cents a year). &nbsp;
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $408,650 or around 8,333 shares. For a more modest $100 per month or $1,200 per year, you would need $81,750 or around 1,667 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($0.72 in this case). So, $6,000 / $0.72 = 8,333 ($500 per month), and $1,200 / $0.72 = 1,667 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
CMC Price Action: Shares of Commercial Metals rose 0.2% to close at $49.04 on Wednesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45993572/top-2-industrials-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Industrials Stocks That May Fall Off A Cliff In Q2</a></li>
</ul>
Photo: Shutterstock

Earnings

Long Ideas

News

Dividends

Markets

Trading Ideas

How To Earn $500 A Month From Commercial Metals Stock Ahead Of Q3 Earnings

Wells Fargo analyst Praneeth Satish maintains Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Overweight and lowers the price target from $65 to $42.

Price Target

Analyst Ratings

ENPH

Wells Fargo Maintains Overweight on Enphase Energy, Lowers Price Target to $42

WIIM

AIFF

Firefly Neuroscience shares are trading higher after the company. announced a breakthrough in Alzheimer's detection using combined EEG/ERP and vMRI.

Wells Fargo analyst Michael Blum maintains Array Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) with a Equal-Weight and raises the price target from $7 to $8.

ARRY

Wells Fargo Maintains Equal-Weight on Array Technologies, Raises Price Target to $8

XXII

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

UNCY

Wedbush analyst Robert Driscoll reiterates Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) with a Outperform and maintains $36 price target.

Reiteration

KURA

Wedbush Reiterates Outperform on Kura Oncology, Maintains $36 Price Target

Investor optimism surrounding a potential XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) exchange-traded fund (ETF) has <a href="https://www.benzinga.com/etfs">reached new heights</a>. 
What Happened: Bettors on the Polymarket prediction platform are assigning an 89% chance of U.S. approval for XRP ETF by the end of 2025.
This surge in confidence, up from 70% earlier this year, reflects growing expectations that XRP could soon join Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) in the ETF arena, potentially reshaping the altcoin market. 
Trading activity on Polymarket has also intensified, with volumes <a href="https://polymarket.com/event/ripple-etf-approved-in-2025?tid=1750364809325">exceeding </a>$95,000, signaling strong market interest driven by regulatory developments and insider sentiment.
An XRP ETF would allow investors to gain exposure to the cryptocurrency through traditional stock exchanges, eliminating the need for managing digital wallets. 
Also Read: <a href="https://www.benzinga.com/markets/tech/25/06/46016990/apple-google-and-facebook-among-services-exposed-in-massive-leak-of-more-than-16-billion-login-records">Apple, Google and Facebook Among Services Exposed In Massive Leak of More Than 16 Billion Login Records</a>
Why It Matters: If approved, an XRP ETF could serve as a pivotal moment for Ripple — the company that created it — and pave the way for greater institutional adoption.
For traders, anticipating ETF approval will likely fuel volatility, creating opportunities for significant price movements as the decision deadline nears.
However, the U.S. Securities and Exchange Commission (SEC) delayed its decision on Franklin Templeton's proposed spot XRP ETF by 35 days. Instead, it opted to open a public comment period.
This delay also affects Franklin Templeton's proposed spot Solana ETF. 
Despite the postponement, 3iQ XRP ETF was launched on the Toronto Stock Exchange on June 18 this year.
The rising odds of U.S. approval highlight a broader trend of cryptocurrencies transitioning into regulated investment vehicles. 
Bitwise and Grayscale have also filed for XRP-related investment products. No approvals have been granted in the U.S. as yet.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46016723/mantles-tim-chen-explains-why-layer-2-ecosystems-are-critical-despite-retail-hesitation">Mantle&#8217;s Tim Chen Explains Why Layer 2 Ecosystems Are Critical Despite Retail Hesitation</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$XRP

Why XRP Could Be The Next Big ETF Bet And What Polymarket Traders Know That You Don't

Wedbush analyst Matt Bryson initiates coverage on NCR Atleos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NATL#NYSE">NATL</a>) with a Outperform rating and announces Price Target of $35.

Initiation

NATL

Wedbush Initiates Coverage On NCR Atleos with Outperform Rating, Announces Price Target of $35

<a href="https://www.globenewswire.com/Tracker?data=HMXwERE9PQskd73yKQRzMih2mDrTOTJc3AP_16WsqAFlMeJPPFgyAIBJX3VCN6_ztabx0RwDCPeoQVGtJtkOgq661KIk8QWPirFVAzu8o1hBSJH97uk1KOiYQIFgKlVKbEaDlFhV_XxCvAnkRvuaPkbNTlqegEvedh44GQ7FCyMWwqmv-bgTkc4JL2u14Snrub3Zv4007KtxIVphj9xMKg==">The poster</a> described an analysis of 40 cytokines, chemokines, soluble cell receptors, and growth factors (CCSGs) from plasma samples obtained prior to treatment from all patients enrolled in Actuate-1801 Part 3B. The analysis identified 7 biomarkers as uniquely significant predictors of favorable survival in the elraglusib-treated cohort, including one, CXCL2, with an inverse survival trend compared to the GnP control arm. This indicates that in patients not treated with elraglusib, high CXCL2 was unfavorable, but this trend is reversed with elraglusib treatment, highlighting the potential of elraglusib to favorably affect the immune microenvironment.

Biotech

General

ACTU

Actuate Therapeutics Highlights Biomarker, Machine Learning Data From Phase 2 Elraglusib Trial In First-Line Treatment Of  Metastatic Pancreatic Cancer

Wedbush analyst Daniel Ives reiterates Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Outperform and maintains $500 price target.

TSLA

Wedbush Reiterates Outperform on Tesla, Maintains $500 Price Target

You don't need to make reckless bets in the stock market or fall for scammy investment schemes to lose money. Sometimes, the biggest threats to your financial future are the quiet, unassuming habits that slowly drain your wealth in the background. They rarely make headlines, and they don't feel dramatic in the moment—but over time, they quietly erode your ability to build lasting security. These are the seven silent wealth drains that might already be working against you—and what to do about each one before they permanently set you back.
<h2 class="wp-block-heading">1. Lifestyle Creep</h2>
This one happens slowly, almost invisibly. You get a raise, and suddenly your $2,000 vacation becomes a $6,000 luxury escape. The sensible car you were perfectly happy with now feels "beneath you," and it gets swapped out for something flashier. The takeout orders increase, the impulse Amazon purchases multiply, and the monthly bills balloon—not because you needed more, but because you could afford more.
The problem? Every time your income rises and your spending rises with it, you&#8217;re robbing your future self of the opportunity to build wealth. That extra $10,000 a year could have gone into your IRA, into real estate, into a brokerage account compounding quietly for the next 30 years. Instead, it gets absorbed into an upgraded lifestyle that feels normal almost immediately—and hard to scale back.
The fix isn't deprivation—it's discipline. Lock in your lifestyle before the raise. If you get a $10,000 raise, try saving or investing at least $5,000 of it before you touch the rest. Future-you will thank you.
Related:
<ul class="wp-block-list">
<li>This Jeff Bezos-backed startup will allow you to <a href="https://arrivedhomes.go2cloud.org/aff_c?offer_id=15&amp;aff_id=1006&amp;aff_sub=yahoo&amp;aff_sub2=byerscta100">become a landlord in just 10 minutes, with minimum investments as low as $100</a>.</li>
<li>Put your money to work for you: In terms of getting money back, <a href="https://www.gobankingrates.com/best-banks-c/">these bank accounts put traditional checking and savings accounts to shame</a>.</li>
</ul>
<h2 class="wp-block-heading">2. Subscription Sprawl</h2>
You probably don't even know how many subscriptions you're currently paying for. Between streaming services, news sites, productivity apps, forgotten software trials, and gym memberships that seemed like a good idea in January, these recurring charges are the financial equivalent of death by a thousand cuts. $9.99 here, $14.99 there—individually, they're harmless. Collectively, they're often hundreds, sometimes thousands of dollars a year.
What makes this so dangerous is how invisible it is. These aren't big, emotional purchases you consciously weigh—they're quiet, autopilot charges that keep hitting your credit card month after month. And every dollar wasted on a forgotten subscription is a dollar not earning compound returns somewhere else.
The solution? Set a calendar reminder every 3–6 months to audit your subscriptions. Open your bank and credit card statements, sort by recurring charges, and get ruthless. If it doesn't spark value, cut it. Let "set it and forget it" become "set it and review it."
<h2 class="wp-block-heading">3. High-Interest Debt</h2>
Credit card balances. Buy-now-pay-later loans. Personal loans with double-digit interest rates. These might feel manageable—just $3,000 or $4,000 spread across a couple of cards—but they're often doing more financial damage than you realize. With interest rates of 20% or more, even a modest balance can snowball into a mountain of debt that's hard to escape.
Here's the math: if you&#8217;re making the minimum payment on a $5,000 credit card at 20% interest, it can take over a decade to pay it off—and you'll likely pay more than double in total. That's money that could've been earning for you instead of bleeding out to lenders.
Before you even think about investing, attack your high-interest debt with laser focus. Every dollar you put toward it gives you a "return" equal to the interest rate you&#8217;re avoiding. Once it's paid off, redirect those payments toward long-term savings and investments.
<h2 class="wp-block-heading">4. Idle Cash</h2>
There's nothing wrong with keeping cash on hand—but too much of it sitting in the wrong place is quietly working against you. If you've got thousands languishing in a checking account earning 0.01% interest—or worse, under your mattress—it's not just doing nothing. It's actively losing value to inflation.
Inflation doesn't feel like a bill, but it functions like one. If inflation runs at 3% and your cash is earning 0.01%, your purchasing power is shrinking year after year. That emergency fund that felt solid five years ago may no longer cover the same expenses today.
A better approach is to segment your cash. Keep 3–6 months of essential expenses in a high-yield savings account or money market fund—somewhere safe, but with a real return. Everything beyond that should be working harder for you: invested in diversified assets that historically outpace inflation and help your money grow.
<h2 class="wp-block-heading">5. Fees You Don't See</h2>
You probably wouldn't knowingly pay $10,000 a year to someone just to manage your investments—but many people do exactly that without realizing it. Hidden fees in mutual funds, advisory charges, transaction costs, and seemingly harmless 1% management fees can quietly siphon six figures from your portfolio over time.
Let's break it down. A 1% annual fee on a $500,000 portfolio is $5,000 per year. Over 30 years, with compounding lost, that can easily cost you over $150,000. That's not pocket change—that's retirement years shaved off the back end.
What can you do? Start by getting clarity. Ask your advisor to spell out all fees in plain English. Use low-cost index funds or ETFs where possible, and favor platforms that minimize transaction and management fees. A few percentage points saved here and there can add up to serious money decades down the line.
Trending: 
<ul class="wp-block-list">
<li>Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/cancervax-advertorial-y2">Back a bold new approach to cancer treatment with high-growth potential.</a></li>
<li>Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this company with similar breakout potential. Learn how you can <a href="https://www.benzinga.com/money/mode-mobile-accredited-investor-y2">invest with $1,000 at just $0.30/share.</a></li>
</ul>
<h2 class="wp-block-heading">6. Delayed Investing</h2>
There's always a reason to wait. The market feels uncertain. You don't have enough saved. You're still learning. But while you're on the sidelines, time keeps ticking—and that's the one resource you can't get back.
The reality is this: the earlier you start, the less you have to invest to reach the same goal. That's the magic of compounding. Delay by five years, and you may need to double your monthly contributions just to catch up. And let's be honest—no one ever feels fully "ready" to invest. There will always be a new headline, a looming recession, or a market dip to worry about.
Start small. Automate contributions. Let the habit build. Because in investing, time in the market always beats timing the market.
<h2 class="wp-block-heading">7. Ignoring Inflation</h2>
You might not see it, but inflation is constantly nibbling away at your purchasing power. The $1,000 you tuck under your mattress today will not buy $1,000 worth of goods a decade from now. Over 20–30 years, that erosion becomes dramatic—especially when you&#8217;re planning for retirement or other long-term goals.
A gallon of milk, a tank of gas, a doctor's visit—these things will cost more in the future. If your money isn't growing at least as fast as inflation, you're falling behind even if your balance stays the same.
The fix is planning with inflation in mind. Don't just look at nominal dollars—think about what those dollars will actually buy in the future. Prioritize investments like stocks, real estate, and Treasury Inflation-Protected Securities (TIPS) that tend to outpace inflation over time. Safe doesn't always mean smart when it comes to long-term wealth.
<h2 class="wp-block-heading">The Takeaway</h2>
You don't have to blow your money to lose it. These silent wealth drains work quietly, month after month, year after year. They don't grab your attention like a bad stock pick or a big splurge, but they do just as much damage—if not more—because they often go unnoticed until it's too late.
Wealth isn't just about what you earn—it's about what you keep, what you grow, and what you don't leak out the sides. Fixing these issues doesn't require genius or a windfall. It just takes awareness, a little strategy, and a willingness to plug the holes early.
Clean up the leaks. Redirect those dollars toward your future. Let your money do what it was always meant to do: build a life that feels free, secure, and fully yours.
See Next: 
<ul class="wp-block-list">
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://arrivedhomes.go2cloud.org/aff_c?offer_id=15&amp;aff_id=1006&amp;aff_sub=yahoo&amp;aff_sub2=jeffbezos100"> Here&#8217;s how you can earn passive income with just $100.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://benzingapartners.go2cloud.org/aff_c?offer_id=532&amp;aff_id=1">you can become an investor for $0.80 per share today.</a></li>
</ul>
<h2 class="wp-block-heading">Want a Second Opinion on Your Finances?</h2>
If you're serious about plugging the leaks and building a more intentional financial future, <a href="https://www.rm2djk4ss.com/BW4BPX/J8P3N/">Wiser Advisor can help</a>. Its platform connects you with experienced, vetted fiduciary advisors who can break down your money situation, uncover the quiet drains you might be missing, and map out a smarter path forward for free.

Personal Finance

7 Silent Wealth Drains That Are Sabotaging Your Future

A popular crypto trader is raising concerns about the price stability of Dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>), a popular meme coin rivaling Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>). 
The trader, known online as Altcoin Sherpa, <a href="https://x.com/AltcoinSherpa/status/1935699918649536605">shared </a>with his 248,000+ followers on X (formerly Twitter) that WIF must maintain a key support level of $0.78 or risk entering a prolonged downward trend.
"WIF needs to hold these levels or a broader decline may follow for similar tokens," he wrote, suggesting that many lower-timeframe charts already show bearish structures.
WIF is currently trading at $0.8001, up about 0.5% over the past 24 hours.
In a separate observation, Sherpa <a href="https://x.com/AltcoinSherpa/status/1935687524313391241">shared </a>a technical chart indicating that Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) could be preparing for a breakout toward an all-time high near $124,000. 
Despite prevailing economic uncertainty, he remains optimistic.
He pointed to ongoing geopolitical tensions and the lack of interest rate cuts, yet noted, "BTC is still above $100,000? That's bullish."
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46016723/mantles-tim-chen-explains-why-layer-2-ecosystems-are-critical-despite-retail-hesitation">Mantle&#8217;s Tim Chen Explains Why Layer 2 Ecosystems Are Critical Despite Retail Hesitation</a>
Still, he urged caution. 
A surprise event or unfavorable news could trigger a sharp drop below $100,000, he said. "I'm not jumping into many trades at the moment. I'm fine holding some losing positions for now. Better to be patient and use this time for research."
At the time of writing, Bitcoin was priced at $105,980, up about 1% for the day.
The trader also <a href="https://x.com/AltcoinSherpa/status/1935665703362932742">commented </a>on Hyperliquid (CRYPTO: HYPE), a newer layer-1 blockchain project. According to his analysis, the token may revisit support around $31.84 if Bitcoin experiences further volatility.
"HYPE might dip into the low $30s if BTC continues to trade sideways or declines. Still, it's one of the stronger performers this cycle, and I'm holding my staked position," he wrote.
HYPE was trading at $37.2 at the time of reporting, down over 3% in the past 24 hours.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46016990/apple-google-and-facebook-among-services-exposed-in-massive-leak-of-more-than-16-billion-login-records">Apple, Google and Facebook Among Services Exposed In Massive Leak of More Than 16 Billion Login Records</a></li>
</ul>
Photo: Shutterstock

$DOGE

$WIF

Trader Warns Dogwifhat Could Trigger Meme Coin Meltdown If Key Level Breaks

Wells Fargo analyst Derek Archila maintains aTyr Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) with a Overweight and raises the price target from $17 to $25.

ATYR

Wells Fargo Maintains Overweight on aTyr Pharma, Raises Price Target to $25

Wedbush analyst Jay McCanless maintains Builders FirstSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) with a Outperform and lowers the price target from $190 to $145.

BLDR

Wedbush Maintains Outperform on Builders FirstSource, Lowers Price Target to $145

Wells Fargo analyst Aaron Rakers maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Overweight and raises the price target from $130 to $150.

Wells Fargo Maintains Overweight on Micron Technology, Raises Price Target to $150

Wells Fargo analyst Steven Cahall maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Overweight and raises the price target from $1222 to $1500.

NFLX

Wells Fargo Maintains Overweight on Netflix, Raises Price Target to $1500

CMCM

Cheetah Mobile shares are trading higher after the company reported a year-over-year increase in Q1 financial results.

Politics

iShares MSCI Israel Capped Investable Market Index Fund

Israeli, Iranian Governments Both Report Iranian Missiles Fired Toward Israel

Macro Economic Events

Economics

Federal Reserve

Fed's Waller Says We Don't Want To Wait Until Job Market Tanks Before Cutting Rates

Press Releases

Ryoncil® is Now Available for Purchase in the United States

Health Care

First Three Children to Commence Treatment With Ryoncil®

Stem Cell Innovators: 4 Companies Advancing Regenerative Medicine

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

Mesoblast Allogeneic Cell Therapy Products Are Designated 'U.S. Country of Origin' and Not Subject to U.S. Tariffs

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

Management

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

ADIA

CRSP

FATE

MESO

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Aurinia Pharmaceuticals Inc - Common Shares

Aurinia Pharmaceuticals

Beam Therapeutics

Biohaven

CareDx

CG Oncology

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

CureVac

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Dyne Therapeutics

89bio

Amicus Therapeutics

Galapagos NV - American Depositary Shares

Galapagos

GRAIL

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Disc Medicine

Janux Therapeutics

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

MannKind

ARS Pharmaceuticals

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Comments

Mesoblast

Intérêt court

Mesoblast (NASDAQ:MESO) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL